Abstract:Apigenin is an edible plant-derived flavonoid showing anti-tumor activities in vitro and in vivo. Pretreatment with apigenin resulted in cell growth arrest and/or apoptosis in various types of tumors via modulating multiple cell signaling pathways. In the present study, we evaluated interactions between apigenin and ABT263 in multiple colon cancer cell lines. We found that apigenin enhanced ABT263-induced apoptosis in colon cancer cells in a time- and dose-dependent manner. ABT263 alone only resulted in limited cell killing in association with upregulation of Mcl-1, a potential mechanism for acquired ABT263 resistance. Apigenin antagonized ABT263-induced Mcl-1 expression and dramatically enhanced ABT263-induced cell death. Apigenin also suppressed AKT and ERK activation. Inactivation of either AKT or ERK pathway by lentivirus-transduced shRNA or specific small molecule inhibitors synergized with ABT263 to induce cell death, reflecting that AKT and ERK pathways are apigenin targets. Moreover, the synergism between ABT263 and apigenin was associated with the upregulation of Bim and subsequent activation of Bax. Xenograft studies with HCT116 cells in SCID mice showed that the combination treatment with apigenin and ABT263 inhibited tumor growth up to 70% without obvious adverse effects, while either agent alone showed only about 30% inhibition. Collectively, our findings demonstrate a novel and effective strategy to treat colon cancer by combination of ABT263 and apigenin. The combined effect is mediated by apigenin downregulation of Mcl-1, Akt and ERK activities. Citation Format: Huanjie Shao, Kai Jing, Esraa Mahmoud, Xianjun Fang, Chunrong Yu. Modulation of AKT, ERK and Mcl-1 by apigenin sensitizes colon cancer cells to anti-tumor activities of ABT263. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3290. doi:10.1158/1538-7445.AM2013-3290

A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms

Anticancer Mechanism of Apigenin and the Implications of GLUT-1 Expression in Head and Neck Cancers

Apigenin's anticancer properties and molecular mechanisms of action: Recent advances and future prospectives

Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment

Potential therapeutic effects of apigenin for colorectal adenocarcinoma: A systematic review and meta‐analysis

Deciphering the modulatory role of apigenin targeting oncogenic pathways in human cancers

Apigenin in Cancer Therapy: Anti-Cancer Effects and Mechanisms of Action

The Anticancer Potential of Apigenin Via Immunoregulation

Pharmacological Properties of 4′, 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways

The influence of apigenin on cellular responses to radiation: From protection to sensitization

Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of Abt-263

Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer.

Apigenin and its nanoformulations for ameliorating normal tissue toxicity and enhancing tumor response to therapy: A mechanistic viewpoint

Autophagy Inhibition Enhances Apigenin-Induced Apoptosis in Human Breast Cancer Cells.

Uncovering SIRT3 and SHMT2-dependent pathways as novel targets for apigenin in modulating colorectal cancer: In vitro and in vivo studies

Apigenin Induces Both Intrinsic and Extrinsic Pathways of Apoptosis in Human Colon Carcinoma HCT-116 Cells

Abstract 3290: Modulation of AKT, ERK and Mcl-1 by Apigenin Sensitizes Colon Cancer Cells to Anti-Tumor Activities of ABT263.

Apigenin: A Bioflavonoid with a Promising Role in Disease Prevention and Treatment

Apigenin's Modulation of Doxorubicin Efficacy in Breast Cancer

Apigenin inhibits renal cell carcinoma cell proliferation.

Resveratrol: an Overview of Its Anti-Cancer Mechanisms